StockData
Aspire-Lakewood Holdings, Inc. logo

Aspire-Lakewood Holdings, Inc. (ASBP) company profile

ASBPNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ASBPW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 2/30
$8.30+0.24 (+2.98%)

Close on Nov 17, 2026Market cap $11.64MP/E –Yield –

About Aspire-Lakewood

Pharmaceutical Preparations, SIC 2834

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical firm that develops and commercializes novel sublingual delivery technologies designed for known pharmaceuticals and nutraceuticals. Its proprietary delivery mechanism provides rapid sublingual absorption directly into the bloodstream in soluble powder or granule form, bypassing the gastrointestinal tract to minimize side effects and enhance therapeutic efficacy. The company primarily targets emergency care and acute conditions, initially developing a high-dose sublingual aspirin candidate intended for heart attack and stroke prevention, acute pain relief, and emergency intervention. Its planned customer base includes hospitals, specialty care settings, and medical practitioners treating cardiovascular and pain management patients.

The business operates primarily in the United States, planning future overseas distribution through partner arrangements. The company utilizes third-party contract development and manufacturing organizations located in New Jersey and Pennsylvania for production. Aspire Biopharma Holdings maintains its principal corporate headquarters in Estero, Florida.

Summary of the business section of Aspire-Lakewood's latest annual report, written by StockData.

Company profile

Company

Legal name
Aspire-Lakewood Holdings, Inc.
Founded
2021
Headquarters
Estero, FL
Address
23150 Fashion Drive, Suite 232 33928
Phone
(561) 704-8527
Industry
Pharmaceutical Preparations
Incorporated in
E9
Fiscal year ends
December 31
Auditor
Bush & Associates CPA LLC, Las Vegas, Nevada

Stock & identifiers

Ticker
ASBP
Other tickers
ASBPW
Former tickers
PWUP until Feb 20, 2025
Exchange
Nasdaq
IPO date
Feb 22, 2022
Shares outstanding
1M, Aug 7, 2026
Public float
$17.40M, Dec 31, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-40 reverse, Jan 16, 2026
SEC CIK
1847345
CUSIP
738920305
ISIN
US7389203057
FIGI
BBG015STV133
Share class FIGI
BBG015STV142
LEI
529900UC0AFER5IEH285
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Donald G. FellDirector20,000

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Feb 22, 2022
Offer price
$10.00
Securities offered
25,000,000
Gross proceeds
$250.00M
Exchange
Nasdaq
First trading day
Apr 11, 2022
Lock-up ends (est.)
Oct 8, 2022

“Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-half of one redeemable warrant.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 29, 2026Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 9, 2026Name changeName changed from Aspire Biopharma Holdings, Inc. to Aspire-Lakewood Holdings, Inc.
Oct 17, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 26, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 18, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 31, 2025Late filingNotification of late filing
Feb 21, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 21, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 19, 2025DelistingNotice of delisting from exchange (Form 25)
Feb 19, 2025Name changeName changed from PowerUp Acquisition Corp. to Aspire Biopharma Holdings, Inc.
Sep 6, 2024MergerRegistration of securities for a merger or exchange offer (S-4)
Aug 15, 2024Late filingNotification of late filing
May 15, 2024Late filingNotification of late filing
Jan 26, 2024MergerRegistration of securities for a merger or exchange offer (S-4)
Feb 22, 2022IPOInitial public offering priced (424B4 prospectus)
Feb 17, 2022ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?